Richard C. Mulligan
Richard C. Mulligan, Ph.D., (born 1954) is the Mallinckrodt Professor of Genetics at Harvard Medical School,[1][2][3] and Director of the Harvard Gene Therapy Initiative.[4]
He is a Director of Enzon Pharmaceuticals, Inc.,[5] and Biogen Idec, Inc..[6]
Awards
- 1981 MacArthur Fellows Program
- 1983 Searle Scholar [7]
Works
- Lindemann, D., Patriquin, E., Feng, S. and Mulligan, R.C. 1997 "Versatile retovirus vector systems for regulated gene expression in vitro and in vivo". Molecular Medicine 3:466-476.
- Goodell, M.A., Rosenzweig, H-.K., Marks, D.G., DeMaria, M., Paradis, G., Grupp, S.A., Sieff, C.A., Mulligan, R.C. and Johnson, R.P. 1997. "Dye efflux studies suggest the existence of CD34-negative/low hematopoietic stem cells in multiple species". Nature Medicine 3:1337-1345.
- Mach, N., Lantz, C.S., Galli, S.J., Reznikoff, G., Mihm, M., Small, C., Granstein, R., Beissert, S., Sadelain, M., Mulligan, R.C. and Dranoff, G. 1998. "Involvement of interleukin-3 in delayed-type hypersensitivity". Blood 92:778-783.
References
- ↑ http://genetics.med.harvard.edu/faculty/mulligan
- ↑ http://www.hms.harvard.edu/dms/bbs/fac/mulligan.html
- ↑ http://www.dfhcc.harvard.edu/membership/profile/member/689/0/
- ↑ "Richard C. Mulligan", Forbes
- ↑ http://www.enzon.com/index.php?id=175
- ↑ http://articles.latimes.com/2009/jun/04/business/fi-briefs4.S3
- ↑ http://www.searlescholars.net/person/419